Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

6 In contrast, FZOCUS‐1 suggested a numerical trend toward improved PFS with the combination therapy of fuzuloparib plus apatinib over fuzuloparib monotherapy in patients with HRP OC, extending the median PFS by 5.6 months (16.6 vs. 11.0 months), with an HR of 0.73 (95% CI, 0.45–1.19).

also in 728 other papers